DNMT3A and acute myeloid leukemia: For example, pharmacologic inhibition of DOT1 like histone lysine methyltransferase (DOT1L), an enzyme with increased activity in DNMT3A-mutant AML, efficiently eliminated mutant cells both in vitro and in vivo12.